EAGAN, Minn., Sept. 16, 2022 (GLOBE NEWSWIRE) — Predictive Oncology POAI today announced that J. Melville (“Mel”) Engle will retire as Chief Executive Officer and as Chairman and member of the Company’s Board of Directors. To ensure a smooth transition of his duties, Mr. Engle will continue in his role until October 31, 2022. In accordance with leadership succession guidelines, the POAI Board Governance Committee is working on a succession plan to replace Mr. Engle. Engle as CEO.
“It has been a privilege to build and lead a team that embraces innovative ideas that will impact the future of oncology drug development,” said Mr. Engle. “At Predictive Oncology, there is a great deal of wisdom, energy and inspiring work done by people dedicated to the fight against cancer. It is an honor for me to end my career here.”
Mr. Engle, 72, has been with POAI since 2016 when he joined the board. He was appointed Chairman of the Board in January 2020 and was appointed Chief Executive Officer in March 2021. He has been instrumental in growing the company as it has evolved into a partner for pharmaceutical and biotech companies involved in the development of oncology drugs. Under his leadership, Mr. Engle has helped expand the Company’s offering to become a suite of solutions along the drug development continuum, from early discovery to clinical trials.
“We appreciate the vision Mel brought to the company and the impact he has had on our strategic positioning as it positions us for the next phase of growth,” said Bob Myers, POAI’s Chief Financial Officer.
Among his accomplishments at POAI, Engle led efforts to acquire zPREDICTA with the goal of expanding the company’s offering to include the production of 3D tumor models in oncology drug development.
About Predictive Oncology
Predictive Oncology POAI is a knowledge-based company focused on applying artificial intelligence (AI) to develop optimal cancer therapies,…
